Floatz logo

Anti-Cd19 Car T-Cells

Lymphoblastic Leukemia, Acute Adult

KK Women's and Children's HospitalCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

73 Active assets in the Lymphoblastic Leukemia, Acute Adult cohort.

Asset / SponsorPhaseRating
MERCAPTOPURINE ANHYDROUS
Shanxi Bethune Hospital
Phase 4A
Cyclophosphamide
The First Affiliated Hospital of Zhengzhou University
Phase 4BBB
METHOTREXATE
PETHEMA Foundation
Phase 4BBB
DEXAMETHASONE
Shanxi Bethune Hospital
Phase 4BBB
Cytosin-Arabinosid
PETHEMA Foundation
Phase 4BBB

View all 50 →

Same molecule, other indications

Anti-Cd19 Car T-Cells is also rated in:

B-cell acute lymphoblastic leukemiaDormant
CCC
Indicative ·
55 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →
acute lymphoblastic leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →